Longboard Pharmaceuticals

Edit info

Founded: 2020

Location: La Jolla, CA

Employee range: 11 - 50

Clinical stage: Clin1b/Clin2a

Therapy area: Developmental and epileptic encephalopathies, other epilepsies

Drug types: NEU

Lead product: LP352

Funding: $23M stock Feb 2023; $80M IPO Mar 2021; $56M A Oct 2020

longboardpharma.com

linkedin.com

job board

Drug notes:

LP659 Clin0 neurological diseases; LP143 RD undisclosed; nelotanserin RD undisclosed

About:

Longboard Pharmaceuticals is developing therapies for patients with neurological and rare diseases. Many important categories of drugs target G protein-coupled receptors (GPCRs) that regulate various biological processes within cells. Longboard was conceived to advance a portfolio of drugs that are highly selective for GPCs using their expertise in drug development and optimization. Their lead program, LP352, is an oral small molecule that binds the GPCR 5-HT2C, which Longboard is testing as a treatment of seizures associated with patients with Developmental and Epileptic Encephalopathy syndromes.